Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + hydroxybutyl chitosan
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Eye Hospital
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Intranasal, Topical
01
Overview
5-fluorouracil (5-FU) in combination with thermosensitive hydroxybutyl chitosan (HBCS) is an experimental adjuvant therapy being investigated by **Tianjin Medical University Eye Hospital** for the treatment of **chronic dacryocystitis** during endoscopic dacryocystorhinostomy (En-DCR). 5-FU is an antimetabolite that inhibits thymidylate synthase, thereby reducing fibroblast proliferation and preventing the formation of granulation tissue and membranous closure at the surgical anastomosis site. HBCS is a biocompatible, biodegradable, and temperature-sensitive hydrogel that functions as a physical barrier to prevent postoperative adhesions and promote healing. This combination aims to improve the success rate of En-DCR by maintaining the patency of the newly created lacrimal passage.
- Other names
- 5-FU5-fluorouracilHBCShydroxybutyl chitosan
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + hydroxybutyl chitosan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + hydroxybutyl chitosan.